BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2207313)

  • 1. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth.
    Santiago-Schwarz F; Panagiotopoulos C; Sawitsky A; Rai KR
    Blood; 1990 Oct; 76(7):1355-60. PubMed ID: 2207313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.
    Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Guarini A; Tos AG; di Celle PF; Cesano A; Matera L
    Blood; 1990 Oct; 76(7):1349-54. PubMed ID: 2207312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
    Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
    Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases.
    van der Harst D; Brand A; van Luxemburg-Heys SA; Kooy-Winkelaar EM; van Rood JJ
    Blood; 1989 Nov; 74(7):2464-70. PubMed ID: 2804374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
    Vu UE; Pavletic ZS; Wang X; Joshi SS
    Leuk Lymphoma; 2000 Nov; 39(5-6):573-82. PubMed ID: 11342340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
    Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
    J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Davis R; Ragab AH
    Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events.
    Yamauchi A; Taga K; Mostowski HS; Bloom ET
    Blood; 1996 Jun; 87(12):5127-35. PubMed ID: 8652825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells.
    Oblakowski P; Bello-Fernandez C; Reittie JE; Heslop HE; Galatowicz G; Veys P; Wilkes S; Prentice HG; Hazlehurst G; Hoffbrand AV
    Blood; 1991 May; 77(9):1996-2001. PubMed ID: 1708296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
    Maruyama T; Imai Y; Harada K; Okada T; Takano M; Ikeda Y; Toda G; Oka H; Osawa T
    J Biol Response Mod; 1990 Aug; 9(4):378-86. PubMed ID: 2395003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
    Lynch DH; Miller RE
    J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
    Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
    Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.